Article
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2022
Konopleva Marina, Thirman Michael J, Pratz Keith W, Garcia Jacqueline S, Recher Christian, Pullarkat Vinod, Kantarjian Hagop M, DiNardo Courtney D, Dail Monique, Duan Yinghui, Chyla Brenda, Potluri Jalaja, Miller Catherine L, Wei Andrew H
Abstract excerpt
PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax +...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.